Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: Synthesis and radiobiological evaluation

Amino Acids

Volumn 47, Issue 6, 2015, Pages 1135-1153

  De, Kakali ^a   Banerjee, Indranil ^a   Misra, Mridula ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

99mTc; C6 tumor; DOMA; HYNIC; Octreotide; Somatostatin receptor

Indexed keywords

CHELATING AGENT; INDIUM; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN;

ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; EXPERIMENTAL NEOPLASM; ISOTOPE LABELING; PROCEDURES; RAT; SCINTISCANNING; SPRAGUE DAWLEY RAT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; DRUG DELIVERY SYSTEMS; INDIUM; ISOTOPE LABELING; NEOPLASMS, EXPERIMENTAL; PEPTIDES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN;

EID: 84939991582     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-015-1942-0     Document Type: Article

References (31)

1. Arnold R, Simon B, Wied M (2000) Treatment of neuroendocrine GEP tumors with somatostatin analogs: a review. Digestion 62:84-91
2. 99mTc-labeled hydrazine nicotinic acid derivatized chemotactic peptides. Nucl Med Biol 22:25-30
3. Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP (1991) In-111-DTPA-D-Phe1-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors-synthesis, radiolabeling and invitro validation. Life Sci 49(22):1583-1591
4. Barbieri F, Florio T (2011) Characterization of the differential efficacy of somatostatin receptor agonists in the inhibition of the growth of experimental gliomas and identification of the intracellular mechanisms involved. Eur J Clin Med Oncol 3:46-53
5. Behera A, De K, Chandra S, Chattopadhyay S, Misra M (2011) Synthesis, radiolabelling and biodistribution of HYNIC-Tyr3 octreotide: a somatostatin receptor positive tumour imaging agent. J Radioanal Nucl Chem 290(1):123-129
6. 3] octreotide as carriers for somatostatin receptor targeted scintigraphy and radionuclide therapy. Int J Cancer 75:406-411
7. 99mTc-DHPM complex: a potential new radiopharmaceutical for lung imaging studies. J Radioanal Nucl Chem 283:621-628
8. De K, Bhowmik A, Behera A, Banerjee I, Ghosh MK, Misra M (2012) Synthesis, radiolabeling and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy. J Pept Sci 18:720-730
9. 3] octreotide. Bioconj Chem 19:431-438
10. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ (2000) 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 41(6):1114-1119
11. Fischman AJ, Babich JW, Strauss HW (1993) A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 34(12):2253-2263
12. Gandomkar M, Najafi R, Shafiei M, Mazidi M, Ebrahimi SES (2007) Preclinical evaluation of Tc-99m/EDDA/tricine/HYNIC0,1-Nal(3), Thr(8)-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors. Nucl Med Biol 34(6):651-657
13. Graham MM, Menda Y (2011) Radiopeptide imaging and therapy in the United States. J Nucl Med 52:56S-63S
14. Guggenberg EV, Penz B, Kemmler G, Virgolini I, Decristoforo C (2006) Comparison of different methods for radiochemical purity testing of [Tc-99m-EDDA-HYNIC-D-Phe(1), Tyr(3)]-octreotide. Appl Radiat Isot 64:194-200
15. Hanaoka H, Tominaga H, Yamada K, Paudyal P, Iida Y, Watanabe S, Paudyal B, Higuchi T, Oriuchi N, Endo K (2009) Evaluation of 64CU-labeled DOTA-d-Phe1-Tyr3-octreotide(64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors. Ann Nucl Med 23:559-567
16. Koenig JA, Edwardson JM, Humphrey PPA (1997) Somatostatin receptors in Neuro2A neuroblastoma cells: operational characteristics. Br J Pharmacol 120(1):45-51
17. 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys. Nucl Med Biol 31:231-239
18. Kwekkeboom DJ, Krenning EP (2002) Somatostatin receptor imaging. Semin Nucl Med 32:84-91
19. Lamszus K, Meverhof W, Westpha M (1997) Somatostatin and somatostatin receptors in the diagnosis and treatment of gliomas. J Neuro Oncol 35:353-364
20. Laznickova A, Laznicek M, Trejtnar F, Melicharova L, Suzuki KH, Akizawa H, Arano Y, Yokoyama A (2002) Distribution and elimination characteristics of 111In-DTPA-d-Phe1-octreotide and 111In-DTPA-L-Phe1-octreotide in rats. Eur J Drug Metab Pharmacokin 27:37-43
21. Lee TW, Chang SR, Chen ST, Tsai ZT (1998) Convenient solid-phase synthesis of tyr(3)-octreotide. Appl Radiat Isot 49(12):1581-1586
22. 1-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconj Chem 13:721-728
23. Liu S, Edwards DS (1999) Tc-99m-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99(9):2235-2268
24. Maina T, Nock BA, Cordopatis P, Bernard BF, Breeman WAP, van Gameren A, van den Berg R, Reubi JC, Krenning EP, de Jong M (2006) Tc-99m demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with In-111 DOTA-tate. Eur J Nucl Med Mol Imaging 33(7):831-840
25. Nikolopoulou A, Nock BA, Maina T (2006) Tc-99m targeting of Sst(2)-expressing tumors by tetraamine-octreotide: first results in CA20948 cells and rat models. Anticancer Res 26(1A):363-366
26. Okarvi SM (2004) Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 24:357-397
27. Panwar P, Iznaga-Escobar N, Mishra P, Srivastava V, Sharma RK, Chandra R, Mishra AK (2005) Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-egfr antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 4:854-860
28. Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28(7):836-846
29. Storch D, Behe M, Walter MA, Chen JH, Powell P, Mikolajczak R, Macke HR (2005) Evaluation of Tc-99m/EDDA/HYNIC0 octreotide derivatives compared with In-111-DOTA(0), Tyr(3), Thr(8) octreotide and In-111-DTPA(0) octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 46(9):1561-1569
30. Susini C, Buscail L (2006) Rational for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733-1742
31. Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester HJ, Zalutsky MR (2003) Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res 9(5):1868-1876